SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Tangram Doses First Participant in Phase 1 Trial of TGM-148

Tangram said it dosed the first participant in a Phase 1 trial of its bleeding disorder drug TGM-148.

Related stories